| Literature DB >> 31444251 |
Pramod K Srivastava1, Margaret K Callahan2.
Abstract
Low-level inhibition of hsp90 enhances the antigenicity of cells whereas high-level inhibition diminishes antigenicity. The mechanism(s) by which hsp90 determines antigenicity are only partially clear. Regardless, these observations have profound implications in protein trafficking and antigen presentation and suggest a novel way to enhance the potency of existing anticancer agents.See related article by Jaeger et al., p. 6392. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31444251 PMCID: PMC6825573 DOI: 10.1158/1078-0432.CCR-19-2094
Source DB: PubMed Journal: Clin Cancer Res ISSN: 1078-0432 Impact factor: 12.531